JP2022543387A5 - - Google Patents

Info

Publication number
JP2022543387A5
JP2022543387A5 JP2022506618A JP2022506618A JP2022543387A5 JP 2022543387 A5 JP2022543387 A5 JP 2022543387A5 JP 2022506618 A JP2022506618 A JP 2022506618A JP 2022506618 A JP2022506618 A JP 2022506618A JP 2022543387 A5 JP2022543387 A5 JP 2022543387A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543387A (ja
Filing date
Publication date
Priority claimed from DE102019121022.4A external-priority patent/DE102019121022A1/de
Application filed filed Critical
Priority claimed from PCT/EP2020/071655 external-priority patent/WO2021023657A1/en
Publication of JP2022543387A publication Critical patent/JP2022543387A/ja
Publication of JP2022543387A5 publication Critical patent/JP2022543387A5/ja
Priority to JP2025127372A priority Critical patent/JP2025163112A/ja
Pending legal-status Critical Current

Links

JP2022506618A 2019-08-02 2020-07-31 修飾二特異性抗ｃｄ３抗体 Pending JP2022543387A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025127372A JP2025163112A (ja) 2019-08-02 2025-07-30 修飾二特異性抗ｃｄ３抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882364P 2019-08-02 2019-08-02
DE102019121022.4 2019-08-02
US62/882,364 2019-08-02
DE102019121022.4A DE102019121022A1 (de) 2019-08-02 2019-08-02 Rekrutierungsagens, das zusätzlich ein MHC-Molekül bindet
PCT/EP2020/071655 WO2021023657A1 (en) 2019-08-02 2020-07-31 Modified bi specific anti cd3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025127372A Division JP2025163112A (ja) 2019-08-02 2025-07-30 修飾二特異性抗ｃｄ３抗体

Publications (2)

Publication Number Publication Date
JP2022543387A JP2022543387A (ja) 2022-10-12
JP2022543387A5 true JP2022543387A5 (enExample) 2023-08-08

Family

ID=72050824

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506618A Pending JP2022543387A (ja) 2019-08-02 2020-07-31 修飾二特異性抗ｃｄ３抗体
JP2025127372A Pending JP2025163112A (ja) 2019-08-02 2025-07-30 修飾二特異性抗ｃｄ３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025127372A Pending JP2025163112A (ja) 2019-08-02 2025-07-30 修飾二特異性抗ｃｄ３抗体

Country Status (11)

Country Link
US (2) US20210032370A1 (enExample)
EP (1) EP4007778A1 (enExample)
JP (2) JP2022543387A (enExample)
KR (1) KR20220041196A (enExample)
CN (1) CN114206932B (enExample)
AU (1) AU2020325562A1 (enExample)
BR (1) BR112022001902A2 (enExample)
CA (1) CA3148936A1 (enExample)
IL (1) IL290267A (enExample)
TW (1) TW202112824A (enExample)
WO (1) WO2021023657A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
EP3575398A4 (en) * 2017-01-30 2020-11-11 Nippon Medical School Foundation ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
LT3428194T (lt) * 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
IL308258A (en) * 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023205334A1 (en) * 2022-04-20 2023-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Coupling assay for t cell specificity (cats) and method of its use
CN114957487B (zh) * 2022-05-24 2024-01-26 北京先声祥瑞生物制品股份有限公司 一种重组结核分枝杆菌融合蛋白及其在结核诊断中应用
CN119487071A (zh) * 2022-06-24 2025-02-18 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
WO2025008643A2 (en) 2023-07-05 2025-01-09 Enara Bio Limited Bispecific polypeptide molecule
WO2025019817A1 (en) * 2023-07-20 2025-01-23 University Of Utah Research Foundation Multi-specific self-assembled drug-free macromolecular t-cell engagers
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233432A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026025031A1 (en) 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
WO2026082746A1 (en) 2024-10-14 2026-04-23 Immatics Biotechnologies Gmbh Bispecific molecule formulation

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA02005559A (es) 1999-12-06 2004-09-10 Univ Illinois Proteinas de tcr de alta afinidad y metodos.
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10335471B2 (en) 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
LT3428194T (lt) * 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren

Similar Documents

Publication Publication Date Title
JP2022543387A5 (enExample)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
US20220169751A1 (en) Multimeric ox40 binding molecules and uses thereof
US20210388098A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
JP5903382B2 (ja) 治療用ｄｌｌ４結合タンパク質
TWI531377B (zh) 骨關節炎及疼痛之治療
US20250243273A1 (en) Humanized anti-basigin antibodies and the use thereof
US20180208648A1 (en) Gdf11 binding proteins and uses thereof
JP2008542278A5 (enExample)
EP4317186A1 (en) Nanobody targeting bcma and application thereof
JP2021509274A (ja) モノクローナル抗体およびその使用法
US20220306760A1 (en) Igm glycovariants
CA2598510A1 (en) Q3 sparc deletion mutant and uses thereof
TW201741339A (zh) 投與結合至cd33及cd3之雙特異性建構體來用於治療骨髓樣白血病之方 法中
CN108314734A (zh) 抗pd－1单克隆抗体及其应用
CN108276492A (zh) 抗pd－l1单克隆抗体及其应用
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
JP2022513321A5 (enExample)
WO2020119707A1 (zh) 抗il-17a抗体及其应用
JP7405434B2 (ja) ストレス関連障害および癌を治療するための材料および方法
WO2021093753A1 (zh) 一种能够与人4-1bb结合的分子及其应用
WO2025140554A1 (en) Fusion proteins and uses thereof
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体
TW202434635A (zh) 多特異性抗體及其醫藥用途
WO2024193668A1 (zh) 抗ctla-4/抗tigit双特异性抗体及其应用